Artificial Pancreas Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies 2024 [Yahoo! Finance]
Humacyte, Inc. (NASDAQ: HUMA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
Humacyte, Inc. (NASDAQ: HUMA) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $4.00 price target on the stock.
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $15.00 price target on the stock.